Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity.

Gooden MJ, Wiersma VR, Boerma A, Leffers N, Boezen HM, ten Hoor KA, Hollema H, Walenkamp AM, Daemen T, Nijman HW, Bremer E.

Br J Cancer. 2014 Mar 18;110(6):1535-44. doi: 10.1038/bjc.2014.55. Epub 2014 Feb 11.

2.

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL.

Meijer A, Kruyt FA, van der Zee AG, Hollema H, Le P, ten Hoor KA, Groothuis GM, Quax WJ, de Vries EG, de Jong S.

Br J Cancer. 2013 Nov 12;109(10):2685-95. doi: 10.1038/bjc.2013.636. Epub 2013 Oct 17.

3.

Multiple VEGF family members are simultaneously expressed in ovarian cancer: a proposed model for bevacizumab resistance.

van der Bilt AR, van der Zee AG, de Vries EG, de Jong S, Timmer-Bosscha H, ten Hoor KA, den Dunnen WF, Hollema H, Reyners AK.

Curr Pharm Des. 2012;18(25):3784-92. Review.

PMID:
22591424
4.

The role of ATM and 53BP1 as predictive markers in cervical cancer.

Roossink F, Wieringa HW, Noordhuis MG, ten Hoor KA, Kok M, Slagter-Menkema L, Hollema H, de Bock GH, Pras E, de Vries EG, de Jong S, van der Zee AG, Schuuring E, Wisman GB, van Vugt MA.

Int J Cancer. 2012 Nov 1;131(9):2056-66. doi: 10.1002/ijc.27488. Epub 2012 Mar 29.

5.

Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different?

Reitsma W, de Bock GH, Oosterwijk JC, ten Hoor KA, Hollema H, Mourits MJ.

Int J Gynecol Cancer. 2012 May;22(4):579-85. doi: 10.1097/IGC.0b013e31823d1b5c.

PMID:
22274543
6.

Status of cellular immunity lacks prognostic significance in vulvar squamous carcinoma.

de Jong RA, Toppen NL, Ten Hoor KA, Boezen HM, Kema IP, Hollema H, Nijman HW.

Gynecol Oncol. 2012 Apr;125(1):186-93. doi: 10.1016/j.ygyno.2011.12.416. Epub 2011 Dec 8.

PMID:
22155674
7.

Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer.

de Jong RA, Nijman HW, Boezen HM, Volmer M, Ten Hoor KA, Krijnen J, van der Zee AG, Hollema H, Kema IP.

Int J Gynecol Cancer. 2011 Oct;21(7):1320-7. doi: 10.1097/IGC.0b013e31822017fb.

PMID:
21720257
8.

Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.

Vermeij R, de Bock GH, Leffers N, Ten Hoor KA, Schulze U, Hollema H, van der Burg SH, van der Zee AG, Daemen T, Nijman HW.

J Immunother. 2011 Jul-Aug;34(6):516-23. doi: 10.1097/CJI.0b013e31821e012f.

PMID:
21654520
9.

Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer.

Noordhuis MG, Fehrmann RS, Wisman GB, Nijhuis ER, van Zanden JJ, Moerland PD, Ver Loren van Themaat E, Volders HH, Kok M, ten Hoor KA, Hollema H, de Vries EG, de Bock GH, van der Zee AG, Schuuring E.

Clin Cancer Res. 2011 Mar 15;17(6):1317-30. doi: 10.1158/1078-0432.CCR-10-2320. Epub 2011 Mar 8.

10.

The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer.

Eijsink JJ, Noordhuis MG, ten Hoor KA, Kok M, Hollema H, de Bock GH, Nijman HW, Schuuring E, Wisman GB, van der Zee AG.

Hum Pathol. 2010 Dec;41(12):1735-41. doi: 10.1016/j.humpath.2010.04.017.

PMID:
21078436
11.

Potential target antigens for a universal vaccine in epithelial ovarian cancer.

Vermeij R, Daemen T, de Bock GH, de Graeff P, Leffers N, Lambeck A, ten Hoor KA, Hollema H, van der Zee AG, Nijman HW.

Clin Dev Immunol. 2010;2010. pii: 891505. doi: 10.1155/2010/891505. Epub 2010 Sep 15.

12.

Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer.

Leffers N, Fehrmann RS, Gooden MJ, Schulze UR, Ten Hoor KA, Hollema H, Boezen HM, Daemen T, de Jong S, Nijman HW, van der Zee AG.

Br J Cancer. 2010 Aug 24;103(5):685-92. doi: 10.1038/sj.bjc.6605820. Epub 2010 Jul 27.

13.

Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer.

Noordhuis MG, Eijsink JJ, Ten Hoor KA, Roossink F, Hollema H, Arts HJ, Pras E, Maduro JH, Reyners AK, de Bock GH, Wisman GB, Schuuring E, van der Zee AG.

Clin Cancer Res. 2009 Dec 1;15(23):7389-97. doi: 10.1158/1078-0432.CCR-09-1149. Epub 2009 Nov 17.

14.

The prognostic value of TRAIL and its death receptors in cervical cancer.

Maduro JH, Noordhuis MG, ten Hoor KA, Pras E, Arts HJ, Eijsink JJ, Hollema H, Mom CH, de Jong S, de Vries EG, de Bock GH, van der Zee AG.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):203-11. doi: 10.1016/j.ijrobp.2009.03.071.

PMID:
19695437
15.

Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.

Jongen VH, Briët JM, de Jong RA, Joppe E, ten Hoor KA, Boezen HM, Evans DB, Hollema H, van der Zee AG, Nijman HW.

Int J Gynecol Cancer. 2009 May;19(4):670-6. doi: 10.1111/IGC.0b013e3181a47c25.

PMID:
19509570
16.

Effect of tamoxifen on the endometrium and the menstrual cycle of premenopausal breast cancer patients.

Buijs C, Willemse PH, de Vries EG, Ten Hoor KA, Boezen HM, Hollema H, Mourits MJ.

Int J Gynecol Cancer. 2009 May;19(4):677-81. doi: 10.1111/IGC.0b013e3181a47cbe.

PMID:
19509569
17.

Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer.

de Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der Zee AG, Hollema H, Nijman HW.

Gynecol Oncol. 2009 Jul;114(1):105-10. doi: 10.1016/j.ygyno.2009.03.022. Epub 2009 May 2.

PMID:
19411095
18.

Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer.

Leffers N, Gooden MJ, Mokhova AA, Kast WM, Boezen HM, Ten Hoor KA, Hollema H, Daemen T, van der Zee AG, Nijman HW.

Gynecol Oncol. 2009 May;113(2):256-63. doi: 10.1016/j.ygyno.2008.12.030. Epub 2009 Feb 24.

PMID:
19243813
19.

Role of endocervical curettage in the preoperative staging of endometrial carcinoma.

Bijen CB, de Bock GH, ten Hoor KA, Nijman HW, Hollema H, Mourits MJ.

Gynecol Oncol. 2009 Mar;112(3):521-5. doi: 10.1016/j.ygyno.2008.11.023. Epub 2009 Jan 10.

PMID:
19135711
20.

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW.

Cancer Immunol Immunother. 2009 Mar;58(3):449-59. doi: 10.1007/s00262-008-0583-5. Epub 2008 Sep 13.

PMID:
18791714
21.

The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.

de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG.

Br J Cancer. 2008 Jul 22;99(2):341-9. doi: 10.1038/sj.bjc.6604471.

22.

A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants.

Hougardy BM, Reesink-Peters N, van den Heuvel FA, ten Hoor KA, Hollema H, de Vries EG, de Jong S, van der Zee AG.

Int J Cancer. 2008 Sep 15;123(6):1457-65. doi: 10.1002/ijc.23684.

23.

MEIS and PBX homeobox proteins in ovarian cancer.

Crijns AP, de Graeff P, Geerts D, Ten Hoor KA, Hollema H, van der Sluis T, Hofstra RM, de Bock GH, de Jong S, van der Zee AG, de Vries EG.

Eur J Cancer. 2007 Nov;43(17):2495-505. Epub 2007 Oct 18.

PMID:
17949970
24.

Beware of amenorrhea during tamoxifen: it may be a wolf in sheep's clothing.

Mourits MJ, de Vries EG, ten Hoor KA, van der Zee AG, Willemse PH.

J Clin Oncol. 2007 Aug 20;25(24):3787-8; author reply 3788-9. No abstract available.

PMID:
17704431
25.

Loss of MSH2 protein expression is a risk factor in early stage cervical cancer.

Nijhuis ER, Nijman HW, Oien KA, Bell A, ten Hoor KA, Reesink-Peters N, Boezen HM, Hollema H, van der Zee AG.

J Clin Pathol. 2007 Jul;60(7):824-30.

26.

Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7.

Lambeck AJ, Crijns AP, Leffers N, Sluiter WJ, ten Hoor KA, Braid M, van der Zee AG, Daemen T, Nijman HW, Kast WM.

Clin Cancer Res. 2007 Apr 15;13(8):2385-91.

27.

Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort.

Mom CH, Engelen MJ, Willemse PH, Gietema JA, ten Hoor KA, de Vries EG, van der Zee AG.

Gynecol Oncol. 2007 May;105(2):365-72. Epub 2007 Feb 15.

PMID:
17306349
28.

EGFR expression is associated with groin node metastases in vulvar cancer, but does not improve their prediction.

Oonk MH, de Bock GH, van der Veen DJ, Ten Hoor KA, de Hullu JA, Hollema H, van der Zee AG.

Gynecol Oncol. 2007 Jan;104(1):109-13. Epub 2006 Sep 11.

PMID:
16963112
29.

Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies.

de Graeff P, Hall J, Crijns AP, de Bock GH, Paul J, Oien KA, ten Hoor KA, de Jong S, Hollema H, Bartlett JM, Brown R, van der Zee AG.

Br J Cancer. 2006 Sep 4;95(5):627-33. Epub 2006 Aug 1.

30.

Squamous cell carcinoma antigen isoforms in serum from cervical cancer patients.

Roijer E, de Bruijn HW, Dahlén U, ten Hoor K, Lundin M, Nilsson K, Soderstrom K, Nilsson O.

Tumour Biol. 2006;27(3):142-52. Epub 2006 Apr 20.

PMID:
16641548
31.

Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.

Reesink-Peters N, van der Velden J, Ten Hoor KA, Boezen HM, de Vries EG, Schilthuis MS, Mourits MJ, Nijman HW, Aalders JG, Hollema H, Pras E, Duk JM, van der Zee AG.

J Clin Oncol. 2005 Mar 1;23(7):1455-62.

PMID:
15735121
32.

Lymphvascular space involvement: an independent prognostic factor in endometrial cancer.

Briët JM, Hollema H, Reesink N, Aalders JG, Mourits MJ, ten Hoor KA, Pras E, Boezen HM, van der Zee AG, Nijman HW.

Gynecol Oncol. 2005 Mar;96(3):799-804.

PMID:
15721428
33.

Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study.

Reesink-Peters N, Hougardy BM, van den Heuvel FA, Ten Hoor KA, Hollema H, Boezen HM, de Vries EG, de Jong S, van der Zee AG.

Gynecol Oncol. 2005 Mar;96(3):705-13.

PMID:
15721415
34.

Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors.

Arts HJ, de Jong S, Hollema H, Ten Hoor KA, de Vries EG, van der Zee AG.

Int J Oncol. 2005 Feb;26(2):379-84.

PMID:
15645122
35.

Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis.

Berends MJ, Wu Y, Sijmons RH, van der Sluis T, Ek WB, Ligtenberg MJ, Arts NJ, ten Hoor KA, Kleibeuker JH, de Vries EG, Mourits MJ, Hollema H, Buys CH, Hofstra RM, van der Zee AG.

J Clin Oncol. 2003 Dec 1;21(23):4364-70.

PMID:
14645426
36.

The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium.

Mourits MJ, Ten Hoor KA, van der Zee AG, Willemse PH, de Vries EG, Hollema H.

J Clin Pathol. 2002 Jul;55(7):514-9.

37.

Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy.

Mourits MJ, Böckermann I, de Vries EG, van der Zee AG, ten Hoor KA, van der Graaf WT, Sluiter WJ, Willemse PH.

Br J Cancer. 2002 May 20;86(10):1546-50.

38.

Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium.

Mourits MJ, Hollema H, De Vries EG, Ten Hoor KA, Willemse PH, Van Der Zee AG.

Hum Pathol. 2002 Mar;33(3):341-6.

PMID:
11979376
39.

Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment.

Pras E, Willemse PH, Canrinus AA, de Bruijn HW, Sluiter WJ, ten Hoor KA, Aalders JG, Szabo BG, de Vries EG.

Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):23-32.

PMID:
11777619
40.

Tamoxifen treatment and gynecologic side effects: a review.

Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG.

Obstet Gynecol. 2001 May;97(5 Pt 2):855-66. Review.

PMID:
11336777
41.

MLH1 and MSH2 protein expression as a pre-screening marker in hereditary and non-hereditary endometrial hyperplasia and cancer.

Berends MJ, Hollema H, Wu Y, van Der Sluis T, Mensink RG, ten Hoor KA, Sijmons RH, de Vries EG, Pras E, Mourits MJ, Hofstra RM, Buys CH, Kleibeuker JH, van Der Zee AG.

Int J Cancer. 2001 May 1;92(3):398-403.

42.

Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.

Engelen MJ, de Bruijn HW, Hollema H, ten Hoor KA, Willemse PH, Aalders JG, van der Zee AG.

Gynecol Oncol. 2000 Jul;78(1):16-20.

PMID:
10873403
43.

Ovarian cysts in women receiving tamoxifen for breast cancer.

Mourits MJ, de Vries EG, Willemse PH, ten Hoor KA, Hollema H, Sluiter WJ, de Bruijn HW, van der Zee AG.

Br J Cancer. 1999 Apr;79(11-12):1761-4.

44.

Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen.

Mourits MJ, Van der Zee AG, Willemse PH, Ten Hoor KA, Hollema H, De Vries EG.

Gynecol Oncol. 1999 Apr;73(1):21-6.

PMID:
10094875
45.

Schwangerschafts protein 1 (SP1) adds little to the age-related detection of fetal Down syndrome in the first trimester of pregnancy.

Kornman LH, Morssink LP, Ten Hoor KA, De Wolf BT, Kloosterman MD, Beekhuis JR, Mantingh A.

Prenat Diagn. 1998 Oct;18(10):1086-90.

PMID:
9826903
46.

Cervical carcinoma during pregnancy: outcome of planned delay in treatment.

van Vliet W, van Loon AJ, ten Hoor KA, Boonstra H.

Eur J Obstet Gynecol Reprod Biol. 1998 Aug;79(2):153-7.

PMID:
9720834
47.
48.
49.

Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma.

Duk JM, Groenier KH, de Bruijn HW, Hollema H, ten Hoor KA, van der Zee AG, Aalders JG.

J Clin Oncol. 1996 Jan;14(1):111-8.

PMID:
8558185
50.

Supplemental Content

Loading ...
Support Center